Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Vactosertib in Combination With Durvalumab in Patients With Advanced Non-Small Cell Lung Cancer
Phase of Trial: Phase I/II
Latest Information Update: 05 Nov 2019
Price : $35 *
At a glance
- Drugs Durvalumab (Primary) ; Vactosertib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors MedPacto
- 29 Oct 2019 Status changed from not yet recruiting to recruiting.
- 04 Nov 2018 Status changed from planning to not yet recruiting.
- 01 Aug 2018 New trial record